The long-term observation of patients with rheumatoid arthritis who achieved a biological disease-modifying antirheumatic drug-free condition with adalimumab

Satoshi Ito; Shunsuke Sakai; Yoichi Kurosawa; Daisuke Kobayashi; Ryo Okabayashi; Asami Abe; Hiroshi Otani; Kiyoshi Nakazono; Akira Murasawa; Ichiei Narita; Hajime Ishikawa

doi:10.1080/14397595.2020.1823551

The long-term observation of patients with rheumatoid arthritis who achieved a biological disease-modifying antirheumatic drug-free condition with adalimumab

Mod Rheumatol. 2021 Jul;31(4):919-923. doi: 10.1080/14397595.2020.1823551. Epub 2020 Oct 12.

Authors

Satoshi Ito¹, Shunsuke Sakai^{1

2}, Yoichi Kurosawa^{1

2}, Daisuke Kobayashi^{1

2}, Ryo Okabayashi¹, Asami Abe¹, Hiroshi Otani¹, Kiyoshi Nakazono¹, Akira Murasawa¹, Ichiei Narita², Hajime Ishikawa¹

Affiliations

¹ Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan.
² Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

PMID: 32930625
DOI: 10.1080/14397595.2020.1823551

No abstract available

Keywords: adalimumab; biological free conditions; conventional synthetic disease-modifying antirheumatic disease drugs; methotrexate; rheumatoid arthritis.

MeSH terms

Adalimumab* / therapeutic use
Antirheumatic Agents* / therapeutic use
Arthritis, Rheumatoid* / drug therapy
Humans
Methotrexate / therapeutic use

Substances

Antirheumatic Agents
Adalimumab
Methotrexate